Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients

Neuronix Ltd1 site in 1 country32 target enrollmentMarch 2013

ConditionsAlzheimer's Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Alzheimer's Disease
Sponsor: Neuronix Ltd
Enrollment: 32
Locations: 1
Primary Endpoint: ADAS-Cog
Status: Completed
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Non-invasive stimulation of the brain using magnetic and cognitive stimulation by computer for the treatment of Alzheimer patients.

Detailed Description

Synchronized TMS and cognitive training for the treatment of mild to moderate Alzheimer's patients. Treatment is delivered 5 days a week, for 6 weeks, visit is about an hour long. Evaluation is by neuropsychological evaluation at 6 weeks.

Registry

clinicaltrials.gov

Start Date

March 2013

End Date

December 2013

Last Updated

12 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Neuronix Ltd

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Male or female age 60-90 years
•Patients diagnosed with mild or moderate stage of Alzheimer's Disease, according to the DSM-IV criteria.
•MMSE score 18 to 26
•Adas-cog above 17
•Physically acceptable for the study as confirmed by medical history and exam.
•Spouse, family member or professional caregiver agree and capable of taking care and be responsible for the participation of the patient in the study (answering questions regarding the patient's condition and assuming responsibility for medication)
•Agreement to participate in approximately 14 weeks during the study.
•Normal or corrected to normal ability to see and to hear.
•Korean as primary language
•8th grade education minimum

Exclusion Criteria

•Severe agitation;
•Mental retardation;
•Patient lacking capacity to consent to study participation
•Unstable medical condition;
•Use of benzodiazepines or barbiturates during the study and preceding two weeks;
•Pharmacological immunosuppression;
•Participation in a clinical trial with any investigational agent within two weeks prior to study enrollment;
•History of Epileptic Seizures or Epilepsy;
•Contraindication for performing MRI scanning;
•Contraindication for receiving TMS treatment according to a TMS questionnaire;